Yellow fever (YF) 17D vaccine virus, having a 60-year history of safe and effective use, is an ideal vector to deliver heterologous genes from other medically important flaviviruses. A chimeric YF/Japanese encephalitis (JE) virus (ChimeriVax-JE virus) was constructed by insertion of the premembrane and envelope (prME) genes of an attenuated human vaccine strain (SA14-14-2) of Japanese encephalitis (JE) virus between core and nonstructural (NS) genes of a YF 17D infectious clone. The virus grew to high titers in cell cultures and was not neurovirulent for 3-to 4-week-old mice at doses Յ6 log 10 plaque forming units (pfu) inoculated by the intracerebral (IC) route. In contrast, commercial YF 17D vaccine was highly neurovirulent for weanling mice by the same route. Mice inoculated subcutaneously with one dose of Ն10 3 pfu of ChimeriVax-JE virus were solidly protected against intraperitoneal challenge with a virulent JE virus. Genetic stability of the chimera was assessed by sequential passages in cell cultures or in mouse brain. All attenuating residues and the avirulent phenotype were preserved after 18 passages in cell cultures or 6 passages in mouse brains.
INTRODUCTION
Japanese encephalitis (JE) is an acute viral infection of the central nervous system occurring throughout Asia. Approximately 3 billion people live in endemic regions, and JE virus has been recently isolated in previously nonaffected areas of Australia (WHO, 98) . Fifty thousand JE cases are reported officially each year of which 10,000 cases are fatal, and a high proportion of survivors have neurological and psychiatric sequelae. JE virus is a positive-stranded RNA virus within the Flaviviridae family. The virus is transmitted from infected animals, mainly domestic pigs to humans by culicine mosquitoes. The most effective disease control measure is vaccination of humans living in or traveling to endemic areas. Currently three vaccines are available: (1) mousebrain-derived, inactivated vaccine, (2) cell-culturederived, inactivated vaccine, and (3) cell-culture-derived, live attenuated vaccine. The mouse-brain vaccine is the only vaccine that is commercialized internationally. The vaccine is only moderately effective (91%) (Hoke et al., 1988) and requires two primary doses, one booster at 1 year, and subsequent boosters every 3 years. In adults, the mouse-brain vaccine has been associated with a high incidence (0.6%) of allergic reactions and recently several cases of severe disseminated encephalitis have been attributed to the vaccine (WHO, 1998) . Due to the method of manufacture and the requirement for multiple doses, the cost of this vaccine is relatively high. In contrast, a cell-culture-derived vaccine (SA14-14-2 used in China) is less expensive, but it is not produced to international standards and requires at least two doses for full protection (Hennessey et al., 1996) . Therefore an ideal JE vaccine would be produced in an internationally acceptable cell substrate, be genetically stable, require a single dose, and be safe and effective. A model flavivirus vaccine having these properties is the live, attenuated yellow fever (YF) 17D, which has a remarkable record of safety and efficacy over 60 years, induces life-long immunity after a single dose, and is extremely inexpensive to manufacture (Barrett, 1997 , Monath, 1999 .
Recently Chambers et al., (1999) reported construction of a chimeric virus based on the core and NS genes of the YF 17D vaccine strain and prME genes of the SA14-14-2 virus (the Chinese JE vaccine). The chimeric virus had the antigenic specificity of JE virus (neutralized by anti-JE specific antibodies but not by anti-YF antibodies) and was attenuated in mice inoculated by the IC route.
In this paper, we describe the immunogenicity, protective efficacy, and genetic stability (in vitro and in vivo) of the chimeric virus.
RESULTS

Growth of ChimeriVax-JE virus in cell cultures
In Vero cells, the ChimeriVax-JE virus reached Ͼ8 log 10 pfu/ml in 5 days, whereas in LLC-MK2 cells, it grew slower and peaked (6 log 10 pfu/ml) at ϳ6 days.
In diploid rhesus monkey (FRhL) and human (MRC-5) cells, ChimeriVax-JE grew to a lower titer. In FRhL cells inoculated at m.o.i. of 0.01 or 0.1, the chimeric virus grew to a peak titer of 6 log 10 pfu/ml. On Day 3, virus titers at m.o.i. of 1 (5 log 10 pfu/ml) were lower than those at 0.1 or 0.01. The effect of m.o.i. on growth kinetics of the Chi-meriVax-JE virus was also evaluated in MRC-5 cells by using a high titer preparation of the chimeric virus prepared by one additional passage in Vero cells. The virus titer peaked on Day 2 at both m.o.i.s tested (6.2 and 5.9 log 10 pfu for m.o.i. of 2 and 0.2, respectively). In contrast to FRhL cells, higher m.o.i. resulted in higher virus yield in MRC-5 cells.
Nucleotide sequence of the ChimeriVax-JE
Envelope protein genes. The sequence of the JE portion of the chimeric YF/JE virus was determined by RT-PCR analysis of the viral RNA extracted from infected cell monolayers. The deduced amino acid sequence of the envelope protein E gene of the ChimeriVax-JE virus was compared with the published sequences for attenuated SA14-14-2 substrains and virulent SA14 and Nakayama viruses (Table 1) . Six amino acid differences at positions 107, 138, 176, 279, 315 , and 439 distinguish all the attenuated SA14-14-2 substrains from both virulent JE viruses, SA14 and Nakayama. Four additional mutations at 177, 227, 244, and 264 distinguish the ChimeriVax-JE virus from the Nakayama strain. Mutations at positions 177, 243, and 264 seem to be host cell dependent because they are only found in SA14-14-2 virus propagated in primary hamster kidney (PHK) cells (the envelope genes of the ChimeriVax-JE are derived from the PHK passaged virus) but not in SA14-14-2 virus propagated in primary dog kidney (PDK) cells or in the parental SA14 virus. Because the PDK passaged virus has wild-type amino acids at these positions but is attenuated, the mutations at residues 177 and 264 in ChimeriVax-JE are unlikely to play a significant role in attenuation.
Yellow fever virus genes. The complete nucleotide sequence of the ChimeriVax-JE virus was determined and compared with published sequences for other YF 17D vaccine substrains that represent independent passage lineages from the original 17D virus described by Theiler and Smith (1937) (Table 2 ). There are 13 nucleotide and 5 amino acid differences among three 17D vaccine substrains shown in Table 2 . Six nucleotide differences and two amino acid changes were found when sequences of the ChimeriVax-JE virus was compared with the published sequences for its parent strain 17D-204 ATCC. Changes at position 5461, 5641, 8212, and 8581 are silent and do not result in amino acid substitutions. The change at position 4025 results in an amino acid substitution from M to V in the NS2A protein, and the change in position 7319 results in an amino acid substitution from K to E in the NS4B protein.
Attenuation of ChimeriVax-JE in mice
Three experiments were performed to compare the neurovirulence phenotype of the ChimeriVax-JE virus with that of the YF 17D vaccine in suckling and young adult mice (Table 3) . In Experiment 1, ChimeriVax-JE virus or YF 17D vaccine (YF-Vax) were inoculated into groups of 3-to 4-week-old outbred (ICR) mice at varying doses from 5 to 1 log 10 pfu via the IC or the SC routes. None of mice inoculated by the SC route with either vaccine died, whereas all mice inoculated by the IC route with 17D vaccine (Ն3.4 log 10 pfu) succumbed within 7-10 days p.i. All mice inoculated with ChimeriVax-JE virus survived the IC infection and developed neutralizing antibodies against JE virus (data not shown). This experiment demonstrated that the ChimeriVax-JE is not neurovirulent for 4-week-old mice, whereas 17D vaccine is neurovirulent 
Note. ChimeriVax-JE (YF/JE SA14-14-2) is shown in boldface. * Nitayaphan et al. (1990) ; † Aihara et al. (1991) ; ‡ Ni et al. (1995) ; § McAda et al. (1987) .
with an IC LD 50 of 1.6 log 10 pfu. None of these viruses were virulent after IP inoculation of 5.0 log 10 pfu demonstrating, as for SC inoculation, the lack of neuroinvasiveness of both viruses for young adult mice (data not shown). To delineate more precisely the neurovirulence and neuroinvasive properties of the viruses, groups of 3-, 5-, 7-, and 9-day-old mice were inoculated by the IP route with 3.0 log 10 pfu 17D vaccine or with 4.0 log 10 Chi-meriVax-JE virus by the IC route. The 17D vaccine was administered IP because this virus is lethal for adult mice when inoculated by the IC route (as described above) and thus would have killed suckling mice by this route. A control group received a sham IC inoculation with diluent (EMEM containing 10% FBS). Mice were followed for signs of illness and death for 21 days. YF-Vax was neuroinvasive and killed 100% of mice inoculated IP at age 3 or 5 days. Age-specific resistance to neuroinvasion developed ϳ7 days of age (Table 3) .
ChimeriVax-JE was neurovirulent after IC inoculation in mice 3 and 5 days of age. Resistance to neurovirulence appeared around age 7 days, at which point the mortality ratio was 40%. Mortality was higher in 9-day-old mice, suggesting that full expression of age-specific resistance occurs at a higher age than tested. It is also possible that mice in the 9-day age group died of a nonspecific cause. In Experiment 3, groups of 8-day-old mice were inoculated IC with YF 17D (Arilvax) at doses varying between 3.4 log 10 pfu and 1.4 log 10 pfu or with ChimeriVax-JE virus at a fixed dose of 3.5 log 10 pfu. All mice receiving Ն2.4 log 10 pfu of YF 17D virus died of encephalitis. Eight of 12 mice (66%) receiving 1.4 log 10 pfu of YF 17D vaccine died with an average survival time (AST) of 10.5 days. In contrast only 4 of 12 mice (33%) that received 3.5 log 10 pfu of ChimeriVax-JE virus died, with an AST of 9.7 days. These studies demonstrated that ChimeriVax-JE virus is significantly less neurovirulent than commercial YF 17D vaccine viruses.
Replication of ChimeriVax-JE in mouse brain
Because the chimeric virus did not cause clinical signs of illness in young adult mice after IC inoculation, it was interesting to determine whether the virus replicates in brain tissues. As shown in Fig. 1 , the virus grew to a peak titer of ϳ6 log 10 pfu/g of brain on Day 6 p.i. Titers decreased over the subsequent course of observation (through Day 12; Fig. 1 ). We did not determine the time to complete viral clearance from the brains in this experiment. Because brains of three mice were pooled to determine brain virus titers, differences among individual mice were not assessed by this experiment.
Genetic stability of attenuating mutations during in vitro and in vivo passage
In vitro passage. To ascertain that there would be no genetic changes with passages in cell culture during manufacturing of vaccine and to identify if there are ''hot spots'' in the vaccine virus genome where mutations could be selected, three experiments were carried out. In Experiments 1 and 2, ChimeriVax-JE virus was passed 18 times in Vero cells at a m.o.i. of ϳ0. 1. In Experiment 3, ChimeriVax-JE virus was passed 10 times in FRhL cells. At selected pas- 
Note. Bold nucleotides are those that differ between ChimeriVax-JE and published sequence for 17D204ATCC. Shaded areas are where nucleotide changes result in amino acid substitution in ChimeriVax-JE.
a Nucleotide numbers (NT) are from 5Ј terminus of the genome. If a nucleotide change results in an amino acid substitution, the amino acid (AA) is shown from left to right (e.g., from ChimeriVax to 17D204WHO).
b ChimeriVax is the chimeric YF/JE research virus which is 2 Vero and 1 FeRhL passages post transfection. c Rice et al. (1985) . d Dupuy et al. (1989) . e Duarte dos Santos et al. (1995) .
sage levels, duplicate samples of viral genomic RNA were extracted, reverse-transcribed, amplified by PCR, and the prME regions or the complete genome sequenced in parallel as described under Materials and Methods. Neurovirulence tests were performed in 3-to 4-week-old ICR mice by IC inoculation of 0.03 ml of undiluted and serial tenfold dilutions of cell culture fluids harvested at various passages. The FRhL-passaged viruses were also tested for neurovirulence in 8-day-old mice. In Experiment 1, none of the SA14-14-2 mutations putatively involved in attenuation underwent reversion during passage. A single mutation (CAC to CGC) was found at P10 and P18 in the E gene at codon 394 (numbering from the amino terminus of the E protein), leading to amino acid change from H to R. A mixture of A (consensus) and G (mutant) was observed at this position at both passages. In Experiment 2, the SA14-14-2 mutations were also preserved across 18 passages in Vero cells. A single mutation occurred in the E gene at P18 but at a different site than that observed in Experiment 1, indicating that there were no ''hot spots'' for selective mutagenesis in the viral genome. This mutation occurred at E-271 (GTG to ATG), resulting in an amino acid substitution from V to M. This mutation could not be found in P14 or in earlier passages. Again the mutated nucleotide appeared heterogeneous (mixture of consensus and mutant codon). The selected mutations were found in duplicate sam- 
ChimeriVax-JE 4.0 CD-1 (ICR) IC (3 days) 9/9 (100) 10.2 (5 days) 11/11 (100) 10.9 (7 days) 4/10 (40) 11.5 (9 days) 11/13 (85) d 11.0 YF 17D c 3.0 CD-1 (ICR) IP (3 days) 9/9 (100) 9.0 (5 days) 11/11 (100) 11.0 (7 days) 2/10 (20) 10.5 (9 days) 1/10 (10) ples from Experiments 1 and 2, arguing against any RT-PCR artifacts obscuring the data. The full genomic sequence was determined for P18 in Experiment 1. There were no mutations in the yellow fever portion (C or NS regions) of the virus when compared with that of the ChimeriVax-JE virus. Sequencing of the P5 virus produced in FRhL cells revealed no changes in the prME regions, but a nucleotide transversion (from ACA to AAA) was found in P10 that resulted in amino acid substitution from T to K at position 281 in the E protein.
This change was found in both duplicate samples. Neurovirulence phenotypes of P1, P5, and P10 virus passed in FRhL cells and P1, P10, and P18 virus passed in Vero cells were determined in 3-to 4-week-old outbred mice by IC inoculation of various doses (from 3 to 7 log 10 pfu). No mice died, indicating that the attenuation phenotype was maintained across 18 passages in Vero cells (Experiments 1 and 2) and across 10 passages in FRhL cells (data not shown). The P2 and P5 viruses produced in the FRhL MCB were also compared with Chi-meriVax-JE by IC inoculation (3.5 log 10 pfu) into groups of 8-day-old mice. No significant change in mortality rates or AST were observed in mice inoculated with these passages. One of 13, 4 of 13, and 4 of 12 mice died from P2, P5, and ChimeriVax-JE, respectively.
In vivo passage. The stability of the ChimeriVax-JE virus during in vivo passage was examined. Because of the known ability of flaviviruses to become neuroadapted on brain-brain passage in mice (Collier et al., 1959) , we considered this study to be a relevant test of genetic stability of the attenuating mutations of the ChimeriVax-JE virus. It was found that the titer of virus in brains harvested 6 days after IC inoculation was stable across six passages (6 log 10 pfu/g) with no evidence for increasing titer (neuroadaptation). The attenuation phenotype was maintained across 6 pas-sages. All mice (3-to 4-week old) inoculated IC with 3.5 log 10 pfu of brain homogenates from P1 to P6 seroconverted, with neutralizing (N) titers of Ͼ1:80 on Day 21. Mice (3-to 4-week old) immunized SC with 4.5 log 10 pfu of virus at each passage level also developed N anti-JE antibody responses. There was no difference in geometric mean N antibody titers across the test groups. As a more sensitive test of neurovirulence, the P6 virus was tested by IC inoculation of 8-day-old mice. At this age, mice begin to show age-related resistance to IC inoculation of YF 17D and Chi-meriVax-JE viruses. There was no increase in neurovirulence for 8-day-old mice when mouse-brain P6 virus was compared with ChimeriVax-JE. Four of 12 mice inoculated with 3.5 log 10 pfu of P6 or Chi-meriVax-JE virus died (data not shown). These results indicated a high level of genetic stability of the virus in presence of selection for neuroadaptation. Viral RNA sequenced at P6 level revealed no mutation in the E gene. Thus none of the attenuating loci of the E gene was altered during sequential mouse brain passage. A single mutation was observed in the prME sequence, at nucleotide 766 (A to C transversion), causing an amino acid change from Q to P at residue 97. This mutation was observed in both duplicate samples and sequencing of the negative control gave no sequence data as expected. A low-intensity signal (A) was observed in the sequence data, suggesting that a small percentage of the viral population is the original Chi-meriVax-JE virus at this nucleotide position. 
a Reciprocal of the highest dilution of serum that resulted in 50% reduction of plaque numbers.
b The end point titer was not achieved with at least one animal. c Titer less than the lowest serum dilution (1:10) tested.
FIG. 1. Growth kinetics of ChimeriVax-JE virus in mouse brain. Ten groups (n ϭ 4) of 3-to 4-week-old ICR mice were inoculated by the IC route with 3.0 log 10 pfu of ChimeriVax-JE virus. At selected intervals (Day 1-12), brains of four mice were harvested, pooled and homogenized (20% W/V) and virus titers were determined by plaque assay in Vero cells.
Immunogenicity and protection against challenge in mice
Immunogenicity of ChimeriVax-JE and YF-Vax in mice. The immunogenicity of the ChimeriVax-JE research virus was compared with YF-Vax in outbred mice. Groups of five 4-week-old ICR mice were inoculated SC with graded doses of the viruses (Table 4 ). Animals were bled 3 and 8 weeks later, and 50% plaque-reduction neutralizing titers were determined against the homologous virus. The highest neutralizing antibody titers were observed 8 weeks after immunization in mice receiving 5 log 10 pfu of Chi-meriVax-JE virus [geometric mean (GMT) N antibody titer Ն970]. Interestingly, the highest concentration of the YF 17D vaccine did not induce significant titers of neutralizing antibodies 3 or 8 weeks postimmunization, but antibodies were elicited at lower doses. Neutralizing antibody titers in mice that received lower doses of YF-Vax was slightly higher (after 8 weeks) compared with similar groups that received the Chi-meriVax-JE virus. It is likely that the chimeric virus is somewhat less infectious for mice than YF 17D virus. However, when inoculated at an infective dose, the chimera appears to elicits a higher immune response. This may be due to higher replication in or altered tropism for host tissues.
Protection against challenge with virulent JE virus. ChimeriVax-JE virus was evaluated for protection in C57/BL6 mice. We selected these mice because they are susceptible to lethal infection after IP inoculation with certain wild-type JE viruses. Mice were immunized by the SC route with graded doses of viruses and observed for 21 days, at which time surviving animals were bled for determination of anti-JE neutralizing antibody titers. On Day 28 they were challenged by IP inoculation of 158 LD 50 (2000 PFU) of JE virus (IC-37). Protection is expressed as the proportion of mice surviving 21 days after challenge. ChimeriVax-JE virus was effective at protecting mice immunized with Ն10 3 pfu. There was only a single fatality in the group given 10 4 pfu of the ChimeriVax-JE virus (Table 5) ; the 50% protective dose of the chimeric virus was 2.3 log 10 pfu. Animals that received three doses of JE-Vax were solidly protected against challenge, but mice given a single dose of the SA14-14-2 vaccine were poorly protected. As expected, yellow fever 17D virus did not cross-protect against JE challenge. Wild-type Nakayama virus was lethal for a proportion of animals in a dose-dependent fashion; survivors were poorly protected against challenge indicating that the lethal dose was close to the infecting dose for this virus. The YF/JE Nakayama chimeric virus was also neuroinvasive in C57/BL6 mice, and all mice given 5 log 10 pfu of the chimera died after SC inoculation.
DISCUSSION
In this paper, we describe the neurovirulence phenotype, immunogenicity, and genetic stability of a recombinant chimeric YF/JE virus proposed as a live, attenuated vaccine candidate.
Similar to results of growth kinetics in LLC-MK2 and C6/36 cells , the ChimeriVax-JE replicated efficiently in Vero cells. Because at present none of these cell lines is approved as a substrate for live, parentally administered viral vaccines, we explored other approved cell lines (human-and monkey-derived diploid cells) such as MRC-5 and FRhL cells. The chimera grew to similar levels (6 log 10 pfu/ml) with no sign of CPE in both cell lines. The titers declined upon further incubation, particularly in MRC-5 cells. The reason for a low yield at high m.o.i. in FRhL cells or loss of infectious virus from Day 4 to 8 is not clear but may reflect generation of defective interfering particles or interferon. No increase in virus yield in FRhL cells was achieved by addition of 70 mM MgSO 4 and 32°C temperature (Halstead et al., 1984) or interferon inhibitors such as 2-amino- purine and indomethacin (Sekellic and Marcus, 1985; Marcus and Sekellic, 1988; unpublished data) . The neurovirulence phenotype of the chimeric virus in 3-to 4-week-old mice was compared with that of commercial YF 17D vaccines. All mice inoculated by the IC route with YF-Vax died within 7-8 days. In contrast all mice inoculated with ChimeriVax-JE virus survived without signs of illness. None of the mice inoculated with YF-Vax or the ChimeriVax-JE virus by the peripheral (SC or IP) routes showed signs of illness or death. Thus as previously reported (Fitzgeorge and Bradish, 1980) , YF 17D virus was not neuroinvasive in weaned mice. Because the chimeric virus is not neurovirulent, it cannot be determined from these data whether it entered the central nervous system. We showed that the chimeric virus did replicate in mouse brain after IC inoculation, and reached a peak titer of 6 log 10 pfu/g of brain on Day 6 p.i. The virus titers in the brain gradually dropped to almost undetectable levels by Day 12. Similar results were reported with another attenuated recombinant JE virus, IC-47 (Sumiyoshi et al., 1995) . The IC-47 virus peaked at 6 log 10 pfu/g on Day 6 and was cleared from the brain by Day 14, whereas a virus (IC-37) that differed from IC-47 by a single amino acid substitution (K 3 E, position 138 in the E gene) grew to Ͼ8 log 10 pfu/g of brain and killed all mice by Day 5.
Because no mortality was observed in 3-to 4-week-old mice at doses of Յ6 log 10 pfu, we inoculated infant mice (3-to 9-days old) by the IC route with ChimeriVax-JE virus and with YF 17D vaccine by the IP or IC route. Mice became resistant to ChimeriVax-JE virus ϳ7 days of age at which point the mortality ratio was 40%. In another experiment, groups of 8-day-old mice were inoculated IC with a fixed dose of ChimeriVax-JE or graded doses of YF 17D vaccine. Only 33% of mice inoculated with 3.5 log 10 pfu of ChimeriVax-JE died, whereas 100% mice inoculated with 3.4 or 2.4 log 10 pfu of YF 17D died. Thus the neurovirulence in infant mice is a sensitive marker of the attenuation phenotype of the ChimeriVax-JE virus. In sum, the ChimeriVax-JE was less neurovirulent than either of two commercial YF 17D vaccines in suckling and weanling mice. Similar results were obtained when these viruses were inoculated into monkeys by the IC routes. Monkeys inoculated with ChimeriVax-JE had minimal brain and spinal cord lesion scores, which were lower than those inoculated with YF 17D vaccine .
Both wild-type JE Nakayama virus and the YF/JE Nakayama chimeric virus were partially neuroinvasive in C57/BL6 mice inoculated SC. This is consistent with earlier studies in which only 3 of 15 3-week-old C57/BL6 mice died after IP inoculation of the YF/JE Nakayama chimeric virus . There are 10 amino acid differences between the envelope protein of the Chimerivax-JE virus and Nakayama virus. Four of these residues (107, 138, 176, and 279) are suspected to play a critical role in attenuation because (a) they appear only in attenuated SA14-14-2 substrains and in the Chi-meriVax-JE virus; (b) they map within putative functional domains of the E-protein; (c) attenuated vaccine strains of JE (SA14-14-2, SA14-5-3, and SA14-2-8) differ from virulent parent SA14 viruses at four common amino acids (138, 176, 315, and 439) (Ni et al., 1994 (Ni et al., , 1995 ; and (d) a virulence determinant was defined at position 138 by site directed mutagenesis of a full-length JE infectious clone (Sumiyoshi et al., 1995) . In studies to be published elsewhere, site-directed mutagenesis has been used to revert attenuated residues (as single revertant or multiple revertants) to wild-type sequences and evaluate their virulence phenotype in the mouse model (Arroyo et al., unpublished data) . These experiments are relevant to the safety of ChimeriVax vaccine technology because they demonstrate that the attenuation phenotype is not solely dependent on a single amino acid residue.
In protection studies, the survivors from YF/JE Nakayama were fully protected against challenge, whereas those surviving JE Nakayama were not protected (Table  5 ). These results indicated that the lethal dose of JE Nakayama was equivalent to the inoculated dose. In contrast YF/JE Nakayama appeared to be more immunogenic because survivors inoculated with low doses were fully protected. Neutralizing antibody responses in mice immunized with ChimeriVax-JE virus showed a dose response and good correlation with protection. Responses were superior to SA14-14-2, wild-type Nakayama or YF-Vax. Animals that received three doses of the inactivated vaccine (JE-Vax) were also solidly protected. In contrast, those animals immunized with a single dose of the SA14-14-2 vaccine were partially protected; this may indicate the requirement of two doses for full protection as recommended for this vaccine (Hennessy et al., 1996) . As expected animals immunized with YF-Vax or YF 17D infectious clone-derived virus were not protected against JE challenge indicating that protection was due to a type-specific response.
Genetic stability is a major concern for production of any live attenuated viral vaccine. Because of the quasispecies nature of the RNA viruses, it is believed that these viruses are heterogenous in their genome and mutations occurs nonspecifically across the genome. If a mutant gains advantage over the original virus, it will dominate the viral population. In other cases, mutants are either nonviable and eliminated or replicated as noninfectious particles and increase the particle/pfu ratio in the virus population. In case of polio virus type 3, it was shown that propagation of the vaccine in cell culture resulted in rapid selection of virus with reversion at two positions in the genome, one of which was directly associated with neurovirulence of the virus in monkey (Chumakov et al., 1992) . Because of the high mutation rate of RNA viruses, it was necessary to monitor the stability of the attenuating sites that reside mainly on the envelope protein of the ChimeriVax-JE virus. The current ChimeriVax-JE vaccine lot is prepared in FRhL cells and is five passages posttransfection. In practice, the chimeric vaccine will never be passed more than five times in cell cultures, decreasing any chances for reversion. In three different experiments using Vero and FRhL cells, the ChimeriVax-JE virus was passed Յ18 times and was evaluated for its genome stability and virulence phenotype in mice. Although we found one nucleotide change substitution in higher passages (Ն10), we were not able to find any hot spot in the genome where mutations would reoccur. None of the determinants required for attenuation was affected by passage. The chimeric viruses retained their full attenuated phenotype and all mice survived IC inoculation of doses of Յ6 log 10 pfu of all passages tested. This was also true when the chimeric virus was passaged six times in vivo (brain to brain passage in mice).
Genomic heterogeneity was observed when different substrains of YF 17D virus were compared with the ChimeriVax-JE virus within the NS genes, presumably reflecting differences in passage history and plaquepurification of YF 17D viruses (Rice et al., 1985; Dupuy et al., 1989 , Post et al., 1992 Duarte dos Santos et al., 1995; Barrett, 1997) . ChimeriVax-JE virus differed from the published sequence of its parent virus 17D-204 ATCC (Rice et al., 1985) at six nucleotide positions, two of which resulted in amino acid substitutions within the NS2A and NS4B genes. The substitution at nucleotide 4025 (NS2A gene) is unique among 17D strains, whereas the substitution at nucleotide 7319 (NS4B gene) is not unique, occurring in two of three 17D substrains examined. It is remarkable that the sequence of the core and NS genes of the chimeric virus passaged 18 times in Vero cells was identical to the unpassaged ChimeriVax-JE virus. However this is consistent with studies by Xie et al., (1998) demonstrating that YF 17D vaccine accumulate mutations at a low frequency in human vaccinees. Thus it is likely that the core and NS genes of the YF backbone encode determinants that maintain genotype of YF 17D virus.
In addition to the structural proteins of the JE virus (prME) that contain T cell determinants and are involved in induction of long-lasting immunity (Aihara et al., 1998 , Konishi et al., 1997 , NS proteins of flaviviruses are known to be a dominant source of T cell epitopes (Despres et al., 1991; Lobigs et al., 1994; Putnak and Schlesinger, 1990; Monath and Heinz, 1996) . Specifically, the NS1 protein of YF virus has been suggested to be involved in protection against encephalitis in mice by FcR-dependent protection of anti-NS1 antibodies (Schlesinger et al., 1993) . Because the ChimeriVax-JE virus contains NS proteins of the YF 17D virus, preimmunization with YF 17D vaccine could interfere with Chi-meriVax-JE vaccination. Conversely vaccination with Chi-meriVax-JE virus may interfere with seroconversion to YF vaccine. Interference between YF and JE vaccines was studied during a period of 1 year in outbred mice. No evidence for interference was found based on neutralizing antibody responses in animals immunized with Chi-meriVax-JE virus or YF-Vax and reimmunized at intervals of 3, 6, or 12 months with the reciprocal virus (Guirakhoo et al., unpublished data, 1998) . Because of low immunogenicity of YF 17D in mice, we are currently investigating the '' antivector'' immunity in nonhuman primates, which are more susceptible to YF virus infection.
In summary, the ChimeriVax-JE virus appears to have an excellent profile as a live attenuated, single dose vaccine candidate against JE.
MATERIALS AND METHODS
Cells
Vero cells originally obtained from Dr. Joel Dalrymple (USAMRIID) were received from Dr. Thomas Chambers (St. Louis University). LLC-MK2 (CLL-7.1, passage 12), fetal rhesus lung (DBS-FRhL-2 from Macaca mulata, passage 28), and MRC-5 cells (diploid human embryonal lung) were purchased from ATCC. Cells were grown in EMEM, 1% L-glutamine, 1% nonessential amino acids, and 10% fetal bovine serum (FBS) buffered with sodium bicarbonate. A Master cell bank (MCB) of FRhL cells was prepared at passage 19 under contract at Magenta Corp. (Rockville, MD) using FRhL cells obtained from the FDA and ATCC at passage 10.
Plaque reduction neutralization test
Neutralizing antibody titers were determined as described by Monath et al., (1999) . Briefly, sera were heat inactivated, serially diluted, and mixed with an equal volume of virus suspension. The mixtures were incubated at 4°C overnight and added to the Vero cell monolayers. After 1.5-h incubation at 37°C, the first agarose overlay was added and plates were returned to the incubator. Plaques were visualized by addition of a second overlay on Day 4, and 50% neutralizing titers (the highest dilution of the serum sample reducing the number of plaques by 50%) were calculated.
Production and amplification of chimeric YF/JE virus
Construction of chimeric YF/JE virus has been described in detail elsewhere . Briefly, full-length cDNA of the chimeric virus was assembled by ligation of restriction fragments of core and NS genes of the YF 17D vaccine strain and prME genes of the JE SA14-14-2 vaccine strain propagated in YF/JE plasmids. Chimeric RNA was transcribed using the SP6 promoter and was used to transfect Vero cells in presence of Lipofectin (Gibco/BRL). Virus was harvested (Vero 1 ), and amplified to produce a Vero 2 seed stock. This stock was passaged once in FRhL cells. This work was performed by Dr. Dennis Trent, Center for Biological Evaluation, US Food and Drug Administration, Bethesda MD. FRhL cells were inoculated with Vero 2 virus at m.o.i. of 1.0. Virus was harvested 78 h later, made into aliquots, and frozen at Ϫ70°C. Virus titers were determined in Vero, LLC-MK2, and CV1 cells using standard plaque assays and found to be 6.3, 6.2, and 5.2 log 10 pfu/ml in the respective cell lines. This virus is referred to as ChimeriVax-JE in this paper. In addition to ChimeriVax-JE, a chimeric YF/JE Nakayama virus (in which prME genes of SA14-14-2 have been replaced with wild-type Nakayama virus) was included in protection studies. All recombinant DNA work was approved by institutional biosafety committee before initiation.
Other viruses
Virulent JE virus (IC-37) was derived from a full-length infectious clone of the JE virus strain JaOArS982, as described by Sumiyoshi et al. (1995) . This virus was propagated in Vero cells to make a seed stock. IC-37derived virus was found to be the most lethal virus for several strains of mice having an intraperitoneal (IP) pfu/LD 50 of 12.6 and therefore was used as challenge virus. The JE Nakayama strain was obtained from CDC, Ft. Collins, CO, and amplified once in Vero and once in HeLa cells. The JE SA14-14-2 virus was one SW13 cell passage of freeze-derived vaccine obtained from Dr. Yu in China. Commercial YF 17D vaccine (YF-Vax) and JE mouse-brain-derived vaccine (JE-Vax) were purchased from Pasteur-Merieux-Connaught Laboratories, Swiftwater, PA. In some experiments, a second YF 17D vaccine (Arilvax, Medeva Pharma Ltd, Speke, UK) was used instead of YF-Vax. All current commercial 17D vaccines are produced at passage level between 233 and 239 from a WHO primary seed (designated 17D-213-77) free from avian leukosis virus. YF5.2iv, a molecular clone of the YF 17D strain (Rice et al., 1989) , was passaged twice in Vero cells after transfection.
Mouse experiments
For studies of neurovirulence, mice of different ages were inoculated by the intracerebral (IC) route. Three-to 4-week-old ICR mice were purchased form Taconic Farms, Inc. (Germantown, NY). Suckling mice (3-to 9-days old) were born on site from pregnant ICR female mice purchased from Taconic or from pregnant female CD-1 (ICR) mice purchased from Charles River Laboratories (Wilmington, MA). For studies of immunogenicity and protection against challenge, we used C57/BL6 mice purchased from Harlan Sprague-Dawley (Indianapolis, IN). C57/BL6 mice were selected because they are susceptible to lethal infection after IP inoculation with certain virulent JE viruses, whereas outbred mice are not uniformly susceptible. C57/BL6 mice were immunized subcutaneously (SC) with graded doses of virus in 100 l and challenged 28 days later with 2000 pfu (equivalent to 158 LD 50 ) of IC-37 virus by the IP route. Animals were observed for 21 days and deaths were recorded. Moribund animals were euthanized under anesthesia.
For in vivo genetic stability studies, two groups of 3-to 4-week-old-ICR mice were inoculated with 3.0 log 10 pfu of ChimeriVax-JE by the IC route. Brains were harvested on Day 6 (previously determined to contain maximum brain virus) from the first group and passed to two new groups of mice by IC inoculation while mice in the second group were observed for 21 days to determine virulence phenotype. This cycle was repeated 6 times (P6). The P6 virus was titrated by plaque assay, and the nucleotide sequence was determined across the prME region and evaluated for its immunogenicity and neurovirulence in mice. All animal work was carried out under protocols approved by the institutional animal care and use committee.
DNA sequencing
Total RNA was extracted from duplicate samples of a 10% (W/V) homogenate of mouse brain or cell culture supernatants using a Qiagen Viral RNA extraction kit (Qiagen, Valencia, CA). Reverse-transcription (RT) was performed with Superscript II reverse-transcriptase (Life Technologies), followed by RNaseH treatment (Promega) and long-PCR (XL PCR, Perkin-Elmer/ABI, Foster City, CA). RT, PCR, and sequencing primers were designed using YF 17D strain sequence (GenBank Accession No. K02749) and JE SA14-14-2 strain sequence (GenBank Accession No. D90195) as references. For whole genome sequencing RT primers used were: yf10.8(Ϫ) 5Ј-AGTGGTTTTGTGTTTGTC and yf5.4(Ϫ) 5Ј-AGTTAACA-ACCCTAGTTG; and PCR primer pairs: yf18(ϩ) 5Ј-AGTA-AATCCTGTGTGCTA and yf7.4(Ϫ) 5Ј-AAGAAGGAGATATA-GAGC; or yf7.2(ϩ) 5Ј-CAGTGATGCCTCTGCTCT and yf10.8(Ϫ). For prME region, sequencing RT primer used was yf2.6(Ϫ) 5Ј-AAGAGGCTTTCACTATTGATG; PCR primer pair was yf0.2(ϩ) 5Ј-ATGGTACGACGAGGAGTTCGC and yf2482(Ϫ) 5Ј-ATCTCCGCACTTGAGCTC. PCR products were gel-purified (Qiaquick gel-extraction kit from Qiagen) and sequenced using Dye-Terminator dRhodamine sequencing reaction mix (Perkin-Elmer/ABI). Sequencing reactions were analyzed on a model 310 Genetic Analyzer (Perkin-Elmer/ABI) and DNA sequences were evaluated using Sequencher 3.0 (GeneCodes) software.
